A prospective controlled study in BMC Medicine reported that adding hepatic arterial infusion chemotherapy to lenvatinib and a PD-1 inhibitor roughly doubled median overall survival in advanced liver cancer patients with portal vein tumor thrombosis. The regimen combines anti-angiogenic therapy with immunotherapy and locoregional drug delivery. The findings are notable because portal vein tumor thrombosis is associated with poor outcomes and limited effective options. For oncology developers, the result supports continued exploration of multi-modality sequencing that leverages both systemic immune priming and improved local tumor control. Clinicians and trial designers will likely focus on patient selection and safety management, since the addition of hepatic arterial infusion can alter toxicity profiles and treatment logistics compared with standard systemic combinations.